Video Experimental Relacionado
Updated: Feb 19, 2026
12:27
A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
Published on: June 8, 2022
4.0K
Nuevos compuestos como inhibidores de LPAR1 para el tratamiento de la esclerosis sistémica
1Arclin USA LLC, 1150 Sanctuary Parkway, Suite 100, Alpharetta, Georgia 30009, United States.
ACS medicinal chemistry letters
|February 18, 2026
Resumen
Se presentan nuevos compuestos que inhiben el receptor 1 de lisofosfatidato (LPAR1). Estos inhibidores de LPAR1 muestran potencial para el tratamiento de la esclerosis sistémica.
Área de la Ciencia:
- Química Medicinal
- Farmacología
- Inmunología
Sus antecedentes:
- La esclerosis sistémica es una enfermedad autoinmune compleja caracterizada por fibrosis.
- El receptor 1 de lisofosfatidato (LPAR1) juega un papel en los procesos fibróticos.
Objetivo del estudio:
- Presentar nuevos compuestos dirigidos a LPAR1.
- Explorar el potencial terapéutico de estos compuestos en el tratamiento de la esclerosis sistémica.
Principales métodos:
- Síntesis de nuevas entidades químicas.
- Evaluación farmacológica de la inhibición de LPAR1.
- Evaluación de la eficacia en modelos preclínicos de esclerosis sistémica.
Principales resultados:
- Se sintetizaron con éxito nuevos inhibidores de LPAR1.
- Estos compuestos demostraron una potente inhibición de LPAR1.
- Los compuestos mostraron ser prometedores en el tratamiento de los fenotipos de la esclerosis sistémica.
Conclusiones:
- Los compuestos desarrollados representan una nueva clase de inhibidores de LPAR1.
- Estos inhibidores tienen una promesa terapéutica para el tratamiento de la esclerosis sistémica.
Videos de Conceptos Relacionados
01:19Antiasthma Drugs: Leukotriene Modifiers
1.9K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.9K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
529
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
529
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
492
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
492
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
633
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
633
01:29Pharmacogenomics: Identification of New Drug Targets
20
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
20